LUVOX (fluvoxamine maleate) by ANI Pharmaceuticals is neurons. First approved in 2007.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
LUVOX (fluvoxamine maleate) is an oral selective serotonin reuptake inhibitor (SSRI) approved for psychiatric and anxiety disorders. It works by potently inhibiting serotonin reuptake in neurons, increasing synaptic serotonin availability. The drug is indicated for obsessive-compulsive disorder, social anxiety disorder, and panic disorder in adults and children.
As LOE approaches, brand team size and commercial investment are likely declining; career growth opportunities favor immediate impact work over long-term brand building.
neurons. Fluvoxamine has been shown to be a potent inhibitor of the serotonin reuptake transporter in preclinical studies, both in vitro and in vivo .
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers
Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects
A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects
A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers
Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.
Worked on LUVOX at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on LUVOX as an LOE-approaching product offers limited career growth but strong operational learning in cost-based competition and generic transition management. Professionals should expect focus on customer retention, compliance, and cost optimization rather than market expansion.